These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26040985)

  • 1. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
    Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
    Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
    Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
    Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
    Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
    Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure-based comparison of two NAMPT inhibitors.
    Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
    Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
    Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
    J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
    Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T
    Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
    Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
    J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
    Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.
    Kesherwani M; Raghavan S; Gunasekaran K; Velmurugan D
    J Biomol Struct Dyn; 2018 Apr; 36(5):1306-1328. PubMed ID: 28514875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
    Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
    Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
    Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW
    J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
    Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.